Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has disrupted health care and has resulted in high mortality rates.(1) Vaccination is an international priority to mitigate the risks of SARS-CoV-2. The initial trials for development of SARS-CoV-2 vaccines excluded individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Millie D., Weaver, Kimberly N., Zhang, Xian, Chun, Kelly, Kappelman, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the AGA Institute 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826602/
https://www.ncbi.nlm.nih.gov/pubmed/35150924
http://dx.doi.org/10.1016/j.cgh.2022.01.056
Descripción
Sumario:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has disrupted health care and has resulted in high mortality rates.(1) Vaccination is an international priority to mitigate the risks of SARS-CoV-2. The initial trials for development of SARS-CoV-2 vaccines excluded individuals with immunocompromising conditions.(2)

Ejemplares similares